Looking to publish in Therapeutic Advances in Hematology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginTherapeutic Advances in Hematology is a peer-reviewed open access journal with a strong clinical and pharmacological focus aimed at clinicians and researchers in hematology.
Looking to publish in Therapeutic Advances in Hematology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Therapeutic Advances in Hematology accepts the following article types. Click on an article type to view submission instructions.
Original Articles
Review Articles
General Reviews
Perspective Reviews
Drug Reviews
Systematic Reviews
Meta-Analyses
Registered Reports – Pre-Data
Registered Reports – Post-Data
Case Reports
Case Series
Brief Reports
Letters To The Editor
Recent Publications
Leveraging absolute reticulocyte count and reticulocyte percentage to differentiate pure red cell aplasia from aplastic anemia
Jimmy Lee, Isa Faghihi, Mutlu Mete, Hussein Awada, Ana Plesca, Serhan Unlu, Valeria Visconte, Carmelo Gurnari, Jaroslaw P. Maciejewski, Taha Bat
Real-life venous thromboembolism risk scores in multiple myeloma receiving daratumumab, lenalidomide, and dexamethasone
Carmine Liberatore, Matteo Candeloro, Francesca Fioritoni, Nicola Potere, Simone Ciavarella, Desiree Tuosto, Stefano Pulini, Ettore Porreca, Marcello Di Nisio, Mauro Di Ianni
Benefit of haploidentical hematopoietic stem cell transplantation for elderly patients with acute myeloid leukemia in first complete remission: A clinical observational study with in-depth time-dependent analysis
Bingqian Jiang, Haifei Guo, Na Tao, Yanmin Zhao, Yi Luo, Jian Yu, Huarui Fu, Xiaoyu Lai, Lizhen Liu, Yishan Ye, Weiyan Zheng, Jie Sun, Jingsong He, Yi Zhao, Guoqing Wei, Zhen Cai, He Huang, Jimin Shi
Low pectoralis muscle index is associated with inferior survival in standard-risk newly diagnosed multiple myeloma
Se-Il Go, Seok-Ho Yoon, Sungwoo Park, Bong-Hoi Choi, Myoung Hee Kang, Eun-Jeong Jeong, Byeong Sun Moon, Gyeong-Won Lee
Clinical efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII in long-term prophylaxis study in patients older than 6 years with severe von Willebrand disease
Cédric Hermans, Balkis Meddeb, Quentin Van Thillo, Alain Gadisseur, Françoise Bridey, Céline Henriet, Anna Klukowska, Emna Gouider
Frequently asked questions
How long does it take to publish?
Accepted articles can appear online within an average of 30 days after APC processing.
Reformat to Therapeutic Advances in Hematology using Livewrite PremiumIs a cover letter required?
A cover letter is required. It should explain why the manuscript is suitable for publication and, if fast-track publication is requested, explain why.
Reformat to Therapeutic Advances in Hematology using Livewrite PremiumWhat are the publication costs?
Article processing charges apply for hybrid open access journals. Institutional agreements, prepaid accounts, or affiliation-based discounts may help cover APCs.
Reformat to Therapeutic Advances in Hematology using Livewrite Premium